JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4 , absent in melanoma 2 ( AIM 2 ) and non-canonical ( NC ) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 ( p20 ), the cleavage of gasdermin D ( GSDMD ), and the releases of IL-1β and lactate dehydrogenases ( LDH ) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1In VivoJC2-11 (250 μg/mouse; i.p.; single dose) significantly inhibits the release of caspase-1 (p20) and IL-1β in non-canonical (NC) inflammatory bodies, and weakens the activation of NC inflammatory bodies of C57BL/6 mice model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice (8 weeks, female) . Dosage: 250 μg/mouse. Administration: Intraperitoneal injection; single dose. Result: Exhibited inhibitory effect on NC inflammatory body.Form:SolidIC50& Target:NLRP3 inflammasome. Specifications and Purity: 98%. Molecular Formula: C17H15FO4. Molecular Weight: 302.30.
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- J648147-10mg
- CAS:
- 937820-89-8
- Product Size:
- 10mg
